Lincoln Pharmaceuticals (531633) Q4 25/26 earnings summary

Executive summary

• Consolidated net profit for FY26 reached Rs. 87.89 crore, up 6.74% year-over-year from Rs. 82.35 crore in FY25.

• Revenue from operations for FY26 was Rs. 704.48 crore, a 9.10% increase year-over-year.

• EBITDA for FY26 stood at Rs. 131.14 crore, up 5.78% year-over-year.

• Q4FY26 revenue grew 13.5% year-over-year to Rs. 183.08 crore; net profit for the quarter was Rs. 11.63 crore.

• Board recommended a dividend of 18% (Rs. 1.80 per share) for FY26.

Financial highlights

• FY26 EPS was Rs. 43.88, up from Rs. 41.11 in FY25.

• Q4FY26 EBITDA was Rs. 20.66 crore, up 4.13% year-over-year.

• Profit before tax for FY26 was Rs. 115.63 crore, up 5.90% year-over-year.

• Total comprehensive income for FY26 was Rs. 89.57 crore.

• FII holding increased to 5.20% as of March 31, 2026; DII holding at 1.08%.

Outlook and guidance

• Targeting Rs. 1,000 crore revenue within three years, aiming for 15-18% annual growth.

• Focused on expanding into high-value product lines and new markets, especially in cardiac, diabetic, dermatology, and ENT segments.

• Plans to expand export footprint from 60+ to 90 countries in 2-3 years.